Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Ascites

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Malignant Ascites. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-000723-15 Sponsor Protocol Number: IP-REM-AC-01 inc. A1,D1,2,3,4,5; Start Date*: 2004-11-15
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM...
    Medical condition: Cancer : Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025538 Malignant ascites LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) GB (Completed) EE (Completed) LV (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001700-39 Sponsor Protocol Number: IP-REM-PK-01-EU Start Date*: 2005-09-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cance...
    Medical condition: epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025538 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018275-20 Sponsor Protocol Number: UMCNONCO201001 Start Date*: 2010-03-24
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
    Medical condition: symptomatic malignant ascites or pleural effusion
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025538 Malignant ascites LLT
    12.1 10026673 Malignant pleural effusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014076-22 Sponsor Protocol Number: IP-CAT-AC-04 Start Date*: 2009-09-23
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after...
    Medical condition: Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing) IT (Completed) BE (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001557-17 Sponsor Protocol Number: IP-CAT-AC-03 Start Date*: 2008-12-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites du...
    Medical condition: malignant ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) FR (Ongoing) BE (Ongoing) GB (Completed) SE (Completed) NL (Ongoing) DK (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000604-16 Sponsor Protocol Number: ARD6772 Start Date*: 2006-08-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites.
    Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005026-31 Sponsor Protocol Number: EFC6125 [AVE0005A/3001] Start Date*: 2006-04-24
    Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ...
    Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014725-16 Sponsor Protocol Number: AIO-SUP-0108 Start Date*: 2010-01-14
    Sponsor Name:AIO Studien gGmbH
    Full Title: Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal c...
    Medical condition: patients with malignant ascites due to advanced-stage gastro-intestinal cancers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003492-29 Sponsor Protocol Number: 391402 Start Date*: 2016-03-02
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 1/2a, Open-Label, Parallel, Two-Arm, Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian...
    Medical condition: Refractory Ovarian Cancer with Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005282-39 Sponsor Protocol Number: AIRC-2013-144445 Start Date*: 2014-05-22
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    Full Title: Effects of high Intra-abdominal pressure on tissue diffusion and pharmacokinectics of cisplatin during HIPEC
    Medical condition: patients affected by peritoneal carcinomatosis from colorectal cancer or pseudomyxoma peritonei
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037138 Pseudomyxoma peritonei PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004585-15 Sponsor Protocol Number: Cat-Ovar_2011 Start Date*: 2012-11-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca...
    Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001429-25 Sponsor Protocol Number: 2011.0704 Start Date*: 2011-08-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Feasibility Study: FES-PET to determine ER-expression in epithelial ovarian cancer
    Medical condition: epithelial ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022810-26 Sponsor Protocol Number: PERCAT01 Version 10, 31.01.2011 Start Date*: 2011-03-16
    Sponsor Name:University Witten/Herdecke
    Full Title: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CH...
    Medical condition: PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068069 Peritoneal carcinomatosis LLT
    12.1 10052360 Colorectal adenocarcinoma LLT
    12.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001552-44 Sponsor Protocol Number: TRIO 015 Start Date*: 2008-09-29
    Sponsor Name:Cancer International research Group
    Full Title: A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY I...
    Medical condition: Recurrent Platinum-sensitive ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020787-37 Sponsor Protocol Number: 8159 Start Date*: 2013-01-28
    Sponsor Name:Universitair Medisch Centrum Groningen
    Full Title: Neo-adjuvant chemotherapy, cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis of colorectal origin (NACHO-trial)
    Medical condition: peritoneal carcinomatosis of colorectal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001660-29 Sponsor Protocol Number: FAB18 Start Date*: 2019-01-16
    Sponsor Name:Leiden University Medical Center
    Full Title: FAB: Functional Analysis of BRCAness
    Medical condition: Recurrent epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003460-24 Sponsor Protocol Number: 82914 Start Date*: 2023-02-23
    Sponsor Name:Radboud University Medical Center
    Full Title: Pilot study to determine the intraTUMORal OsImertinib concentration in patients with peritoneal metastasizeD colorectal cancer (TUMOROID study)
    Medical condition: Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003427-36 Sponsor Protocol Number: M10-898 Start Date*: 2012-04-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advance...
    Medical condition: Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000517-20 Sponsor Protocol Number: CO-338-017 Start Date*: 2013-11-26
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Medical condition: Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016181 Fallopian tube neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003340-30 Sponsor Protocol Number: GM307 Start Date*: 2008-08-21
    Sponsor Name:Genta Incorporated
    Full Title: A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)
    Medical condition: Advanced Melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Ongoing) DE (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA